Brief: Cutia Therapeutics Says Nmpa Accepts Biologics License Application For Cu-20101
03/09/2026 24:47
BRIEF-Cutia Therapeutics Says Nmpa Accepts Biologics License Application For Cu-20101 Sept 3 (Reuters) - Cutia Therapeutics 2487.HK:
CUTIA THERAPEUTICS - NMPA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR CU-20101 (BOTULINUM TOXIN TYPE A) IN CHINA
Further company coverage: 2487.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cutia Therapeutics
See all newsBrief: Cutia Therapeutics To Implement Share Repurchase Program From Oct 2 To Dec 31
Brief: Cutia Therapeutics Says Cu-40102 Bags Marketing Approval From Macao Pharmaceutical Administration Bureau
Brief: Cutia Therapeutics Says Nmpa Accepts Biologics License Application For Cu-20101
Brief: Cutia Therapeutics Posts HY Loss Of RMB180.4 MLN
Brief: Cutia Therapeutics Says CU-30101 Obtains Drug Marketing Authorization By NMPA China